10-K Decoder · All companies

Entrada Therapeutics, Inc.

TRDA · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Feb 2026

Open the dashboardInfographicSummary

FY2025 key figures

$FY2025FY2024Change
Revenue$25.4M$211M−87.9%
Operating income−$158M$47.0M
Net income−$144M$65.6M

Latest quarter: Q3 2026

Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 5, 2026

$Q3 2026Year earlierChange
Revenue$900K$1.60M−43.8%
Operating income−$41.7M−$47.1M+11.5%
Net income−$39.7M−$44.1M+10.0%

Q3 2026 dashboardQ3 2026 infographic

Questions

What was Entrada Therapeutics's revenue in FY2025?
$25.4M in FY2025 (Fiscal year ended Dec 31, 2025), −87.9% vs $211M a year earlier, per its 10-K filed Feb 2026.
Was Entrada Therapeutics profitable in FY2025?
No: net income was −$144M and operating income −$158M in FY2025.
What was Entrada Therapeutics's revenue in Q3 2026?
$900K (−43.8% vs a year earlier), per its Form 10-Q filed Nov 5, 2026.